Supernus Pharmaceuticals, Inc. (SUPN) Q4 FY25 Earnings Call

2026 guidance calls for substantial growth, but Onapco supply execution and higher costs remain key swing factors [35][36].

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-02-26
Length47 minutes
EPS$0.75
Revenue$192.1M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All SUPN earnings ยท Back to SUPN overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.